



CODEN [USA]: IAJPBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

Available online at: <http://www.iajps.com>

Research Article

**ASSESSMENT OF THE RELAXATION AND FEASIBILITY  
OF SALAZOPYRIN IN THE HANDLING OF EXTREME  
ALOPECIA CIRCUMSCRIPTA**<sup>1</sup>Dr. Muhammad Abrar, <sup>2</sup>Dr Madiha Hafeez, <sup>3</sup>Dr. Farheen Nisha<sup>1</sup>THQ Hospital Liaquatpur, <sup>2</sup>University Medical and Dental College, <sup>3</sup>Allied Hospital Faisalabad.

Article Received: November 2020 Accepted: December 2020 Published: January 2021

**Abstract:**

**Objective:** To assess the relaxation and feasibility of Salazopyrin in the handling of extreme Alopecia Circumscripta.

**Methods:** Our current exploration was led at Jinnah Hospital, Lahore from February 2018 to January 2019. This was a valuable non-randomized, flexible first. A total of 45 subjects were evoked for appraisal. Victims were designated from the branch of the Dermatology Unit of the Jinnah Hospital, Lahore. Subjects were experimental with 500mg/day of Salazopyrin at a limit of 4 grams/day. The share for the youths was 10mg/kg/day. Victims were tracked up every two weeks. Sensitive victims were tracked for a supplementary 4 months. All significant evidence was logged and publicized.

**Results:** Four out of 64 victims (7%) responded to conduct. Two of these victims had a mid-response and two had a whole response. There was no important sex dissimilarity in the response to conduct. The important indication experimental was the hepatotoxicity initiate in 5 victims subsequent in interruption of the medication.

**Conclusion:** Salazopyrin is supposed to be abstemiously threatened but not feasible in the conduct of dangerous AA.

**Keywords:** Alopecia universalis, Alopecia Circumscripta, sulphasalazine, alopecia total.

**Corresponding author:**

**Dr. Muhammad Abrar,**  
THQ Hospital Liaquatpur

QR code



Please cite this article in press Muhammad Abrar et al, Assessment Of The Relaxation And Feasibility Of Salazopyrin In The Handling Of Extreme Alopecia Circumscripta., Indo Am. J. P. Sci, 2021; 08(1).

**INTRODUCTION:**

Alopecia Circumscripta (AA) is a resistant arrangement problematic that consequences in uneven masculine design hairlessness deprived of damaging. The disease can happen at any age, but its highest occurrence is in the second and third decade. The disease touches both genders similarly. The auto-immune nature of the disease is suggested by the detection by operation of comprised terrains that show mystical T cell diffusion everywhere the hair cavities [1]. Intralesional corticosteroids are used as first-line treatment for limited summary AA. Intralesional corticosteroids are used as first-line conduct for limited summary AA. They stimulate hair regrowth at the infusion site [2]. It is also connected to other resistant system illnesses such as thyroiditis, vitiligo and malicious anemia. Spartan types of AA comprise broad AA, total alopecia (TA), and universal alopecia (UA). Comprehensive AA is more than 41% masculine pattern hairlessness from hairy zones. Total alopecia is the total nonappearance of hair in the fatal phase of the scalp and universal alopecia is the absolute loss of hair in the terminal phase of the body and scalp [3]. The consequence lasts for a few months and re- handling may sometimes be essential. The dissimilar choices obtainable for limited summary AA are intense topical corticosteroids, dithranol and minoxidil cream. These are endangered, but the consequences of handling are unacceptable. The consequences of handling are not suitable [4]. Thoughtful interesting operatives are used in the handling of dangerous AA. Interesting workers include corticosteroids, monoxides, psoralen handling with light radiation (PUVA), and enthralling. The interesting machinists are used to treat dangerous AA. Monotonous treatments other than verbal and parenteral corticosteroids include Sandimmune. The use of cyclosporine is not suggested for the treatment of extreme AA. Contact immune treatment with di phenyl cyclo propen one (DPCP) or quadratic corrosive dibutyl ester (SADBE) is also suggested for extreme cases of AA. Hair regrowth occurs in about half of cases, but the response rate is much lower in victims with TA and UA. Its restraint is that it is not normally accessible and contains a diversity of hospital visits. Starting point corticosteroids and incessant or thrashing PUVA have been tried to treat extreme AA. As of the deficiency of established competence and the option of true indications, these conducts have not been prescribed to date [5]. The treatment of severe AA has not yet been proven to be effective. In general, replacements to

the handling of dangerous AA are incomplete and do not deliver good consequences. Since they mainly inspiration victim consummation, new restorative alternatives are, in this way, basic. Salazopyrin is a mitigating agent and has been used in numerous resistant system complaints such as rheumatoid inflammation of the joints, psoriasis, and challenging internal infection. It has immune oppressive and immune moderating belongings. There are almost no case intelligences of this medicine being gotten in victims with dangerous AA. Salazopyrin, in this sense, is an substitute that should be examined in the handling of AA.


**METHODOLOGY:**

Our current exploration was led at Jinnah Hospital, Lahore from February 2018 to January 2019. A total of 45 subjects were recalled for review. Victims were selected from the branch of the Dermatology Unit of the Jinnah Hospital, Lahore. This was a useful non-randomized, open-ended preliminary. They were of both sexes, over two years of age and had the disease with the association of more than 27% of scalp territory with or without hair loss on other parts of the body. It was guaranteed that they had no particular prescription for the most recent month. A total of fifty victims, meeting the criteria for consideration, were selected for review. The conclusion of the AA was made clinically. All applicable information, including history, physical assessment and the site, size and degree of alopecia, was recorded in a pro forma. Pre-treatment investigations included a total blood count, renal capacity tests, liver capacity tests, and urinalysis. Criteria for prohibition included victims with evidence of incessant organ failure, e.g., incessant kidney failure, cardiovascular failure, constant liver and lung disease, pregnant and lactating women, and those with extreme sensitivity to salvation from additional drugs and salicylates. The dose was increased by 500 mg steadily to a limit of 43 g/day. Following the underlying workup, victims over 14 years of age received a dose of 500mg/day of Salazopyrin. The most extreme portion was not required in each patient and the determinant in establishing the measurements was hair regrowth. The remainder of the treatment plan is shown in Figure 1. In victims under 1 years of age, the starting dose was 10 mg/kg body weight and was increased steadily by 10 mg/kg to a limit of 70 mg/kg body weight. At each visit, the above-mentioned examinations were repeated every fortnight for the first month and at regular intervals thereafter. The reaction was examined on a scale (Table 1). Victims were

followed up, the first week after the week to the extent necessary to obtain a response and then every two weeks.

**Table 1: Grades of improvement.**

Grade	Recovery (%)
0	No response
1	1-25%
2	26-50%
3	51-75%
4	>75%



**Figure 1: Study protocol for sulphasalazine in Alopecia Circumscripta.**

**Table 2 Age and gender distribution of study population (n=41).**

Group	Total number	Alopecia Circumscripta >25% of scalp area n (%)	Alopecia totalis n (%)	Alopecia universalis n (%)
Females	18	12 (29.3)	3 (7.3)	3 (7.3)
Males	23	13 (31.7)	5 (12.2)	5 (12.2)
Total Number	41	25 (61.0)	8 (19.5)	8 (19.5)


**Table 3: The cure response to sulphasalazine in diverse kinds of Alopecia Circumscripta (n=42).**

Category	Number	No response	Partial response	Total response	Overall response
Alopecia totalis	8	6	1	1	2
Alopecia universalis	8	7	1	0	1
Extensive Alopecia Circumscripta	25	24	0	1	1
Total number	41	37	2	2	4
P value		<0.05	>0.05	>0.05	>0.05

The aspects observed were segment material and remained displayed as up-front measurements. The outcome of medication cure was assessed by hair regrowth. It was connected as either not any reaction or reaction which might be central or comprehensive. The association of reaction A p estimation of <0.06 was measured noticeably remarkable. Evaluations 2 and 3 were viewed as incomplete reaction while grade 4 was taken as all out reaction. SPSS form 23 was applied for our research.

### RESULTS:

Thus, study was done in 43 victims. There were 24 folks and 19 females. 62% victims were of wide AA, and 21% all of alopecia complete is and alopecia universalis. Age and sexual direction apportionment are showed up in Table 2. Sixty victims were from the outset evaluated the examination. There were nine dropouts. Out of them, prescription was stopped in three victims in perspective on agitated liver limit tests. Six victims didn't turn up for advancement.

**Figure 2: Cure reply amongst male and womanly cases.**

None of the victims made hematologic varieties from the standard. The drug was ensured at this point not solid in Alopecia Circumscripta. Concerning impacts, 5 out of 48 victims made clinical and inquire about focus verification of liver damage. Among them two were folks and one female. Sufficiency of medicine is showed up in Table 3. In expansive AA, 2 (8%) understanding showed total response; in alopecia totalis 1 out of 9 (14.7%) victims exhibited total response however sedate was unable in alopecia totalis.

### DISCUSSION:

Regardless, note that the examination relied upon five case reports in a manner of speaking. Likewise, there was no follow-up to see apostatize. The qualification appropriately rates may be a direct result of some racial, genetic or biological components. It may similarly be a direct result of difference in treatment routine and term of therapy [6]. Our assessment demonstrated that sulphasalazine isn't convincing in the organization of genuine Alopecia Circumscripta.

Regardless, our results differentiate from that of study done by Ellis *et al.* in Michigan USA. This is the fundamental examination of sulphasalazine in AA coordinated all around, which showed hair regrowth in 25% cases [7]. Note that when liver hurtfulness occurred in our examination, it did accordingly in starting two months. From this observation we derive that the response of sulphasalazine isn't partition related. It may be an impossible to miss reaction [8]. Minor responses related to gastrointestinal structure were not nitty gritty in our assessment probably due to low estimations when stood out from that used in other resistant framework issue like rheumatoid joint torment and provocative entrapment ailment and moreover because of use of enteric secured tablets. 8% of our victims had disturbed liver limits [9]. It is at any rate ground-breaking in some number of victims. It will in general be an alternative as opposed to the victims who dodge the drawn out usage of jumbled experts. Differentiated and the other treatment modalities, sulphasalazine is up 'til now a desire for sheltered and wide cases that are non-responsive to various strategies for treatment. As for other treatment options for AA like steroids, topical minoxidil, anthralin, PUVA, interferon and dapsone, all have variable responses and upkeep treatment is routinely required. Sulphasalazine is subsequently another development in a broad overview of remedial administrators. [10].

### CONCLUSION:

Further examinations are required to set up its reasonability especially in blend in with other treatment modalities. In the light of present assessment, it is proposed that sulphasalazine is connected with unsatisfactory response in victims with genuine AA.

### REFERENCES:

1. Madani S, Shapiro J. Alopecia Circumscripta update. *J Am Acad Dermatol.* 2000;42:549- 66.
2. Mc Donagh AJ, Tazi-Ahnini R. Epidemiology and genetics of Alopecia Circumscripta. *Clin Exp Dermatol.* 2002;27:405-9.
3. Safavi KH, Muller SA, Suman VJ *et al.* Incidence of Alopecia Circumscripta in Olmsted County, Minnesota, 1975 through 1989. *Mayo Clin Proc.* 1995;70:628-33.
4. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in Alopecia Circumscripta. *J Am Acad Dermatol.* 2005;52:287-90.
5. Friedli A, Labarthe MP, Engelhardt E. Pulse methylprednisolone therapy for severe Alopecia

Circumscripta: an open prospective study of 45 victims. *J Am Acad Dermatol.* 1998;39:597-62.

6. Hordinsky MK. Clinical presentation of Alopecia Circumscripta. *Dermatol Ther.* 2001;14:291-6.
7. Bolduc C, Shapiro J. The treatment of Alopecia Circumscripta. *Dermatol Ther.* 2001;14:306-13.
8. MacDonald Hull SP, Wood ML, Hutchison PE *et al.* Guidelines for management of Alopecia Circumscripta. *Br J Dermatol.* 2003;149:692-9.
9. Ellis CN, Brown MF, Voorhees JJ. Salazopyrin for Alopecia Circumscripta. *Clin Dermatol.* 2002;46:541-5.
10. Van Riel PL, van Gestel AM, van de Putte LB. Long-term usage and side effect profile of sulphasalazine in rheumatoid arthritis. *Br J Rheumatol.* 1995;34:40-6.